Financial Performance - Mogo Inc reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and an improvement from a loss of $0.12 per share a year ago, representing an earnings surprise of 42.86% [1] - The company posted revenues of $12.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.97%, although this is a decline from year-ago revenues of $13.3 million [2] - Over the last four quarters, Mogo has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Mogo shares have declined approximately 19.1% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $11.22 million, and for the current fiscal year, it is -$0.24 on revenues of $45.87 million [7] Industry Context - The Technology Services industry, to which Mogo belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that Mogo's stock may outperform the market based on current estimates [5][6]

分组1 - Wave Life Sciences reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, and compared to a loss of $0.24 per share a year ago, indicating an earnings surprise of -7.41% [1] - The company posted revenues of $9.18 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 34.33%, and down from $12.54 million in the same quarter last year [2] - Wave Life Sciences shares have declined approximately 47.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $18.12 million, and for the current fiscal year, it is -$1.01 on revenues of $66.47 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 33% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Company Performance - Delcath Systems, Inc. (DCTH) reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share, compared to a loss of $0.43 per share a year ago, representing an earnings surprise of -70% [1] - The company posted revenues of $19.78 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.24%, and this is a significant increase from year-ago revenues of $3.14 million [2] - Over the last four quarters, Delcath Systems has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - The sustainability of Delcath Systems' stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The stock has lost about 3.6% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] - The current consensus EPS estimate for the coming quarter is $0.08 on revenues of $19.75 million, and for the current fiscal year, it is $0.28 on revenues of $82.26 million [7] Industry Context - The Medical - Instruments industry, to which Delcath Systems belongs, is currently in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5] - Mesa Labs (MLAB), another company in the same industry, is expected to report quarterly earnings of $2.75 per share, with revenues projected to be $63.1 million, reflecting a year-over-year increase of 7.1% [9]

Core Viewpoint - Stagwell (STGW) reported quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.17 per share, and showing a decline from $0.16 per share a year ago, indicating an earnings surprise of -29.41% [1][2] Financial Performance - The company posted revenues of $651.74 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.93%, and down from $670.06 million year-over-year [2] - Over the last four quarters, Stagwell has surpassed consensus EPS estimates just once, while it has topped consensus revenue estimates three times [2] Stock Performance - Stagwell shares have declined approximately 11.7% since the beginning of the year, compared to a -4.3% decline in the S&P 500 [3] - The company's earnings outlook and management commentary will be crucial for future stock price movements [3][4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.19 on revenues of $697.25 million, and for the current fiscal year, it is $0.86 on revenues of $2.94 billion [7] - The estimate revisions trend for Stagwell is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Advertising and Marketing industry, to which Stagwell belongs, is currently in the top 28% of Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Company Performance - Akebia Therapeutics reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and showing improvement from a loss of $0.09 per share a year ago, resulting in an earnings surprise of 200% [1] - The company posted revenues of $57.34 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 26.83%, compared to year-ago revenues of $32.61 million [2] - Over the last four quarters, Akebia has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Performance - Akebia Therapeutics shares have increased approximately 29.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $44.05 million, and for the current fiscal year, it is -$0.12 on revenues of $192.75 million [7] Industry Outlook - The Medical - Drugs industry, to which Akebia belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Viatris (VTRS) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.04%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.57 per share when it actually produced earnings of $0.54, delivering a surprise of -5.26%.Over the last four quarters, the company ...

Core Viewpoint - Aclaris Therapeutics reported a quarterly loss of $0.12 per share, outperforming the Zacks Consensus Estimate of a loss of $0.17, and showing improvement from a loss of $0.24 per share a year ago, indicating a positive earnings surprise of 29.41% [1] Financial Performance - The company posted revenues of $1.46 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 65.15%, compared to revenues of $2.4 million in the same quarter last year [2] - Over the last four quarters, Aclaris has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Aclaris shares have declined approximately 49.6% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current Zacks Rank for Aclaris is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $4.28 million, and for the current fiscal year, it is -$0.71 on revenues of $17.33 million [7] - The trend of estimate revisions for Aclaris is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Aclaris belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of $0.17 per share, with a year-over-year change of +77.3% [9]

Group 1 - International Seaways reported quarterly earnings of $0.80 per share, exceeding the Zacks Consensus Estimate of $0.59 per share, but down from $2.92 per share a year ago, representing an earnings surprise of 35.59% [1] - The company posted revenues of $183.39 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.17%, compared to year-ago revenues of $274.4 million [2] - International Seaways has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Group 2 - The stock has added about 1.1% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] - The current consensus EPS estimate for the coming quarter is $0.88 on revenues of $183.98 million, and for the current fiscal year, it is $3.65 on revenues of $738.08 million [7] - The Transportation - Shipping industry, to which International Seaways belongs, is currently in the bottom 11% of the Zacks industries, indicating potential challenges ahead [8] Group 3 - Ahead of the earnings release, the estimate revisions trend for International Seaways was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Arhaus, Inc. reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.06 per share, representing a 50% earnings surprise [1] - The company posted revenues of $311.37 million for the quarter, which was 0.55% below the Zacks Consensus Estimate and an increase from $295.16 million year-over-year [2] Financial Performance - The earnings for the same quarter last year were $0.11 per share, indicating a decline in earnings year-over-year [1] - Over the last four quarters, Arhaus has surpassed consensus EPS estimates two times [2] - The company has not beaten consensus revenue estimates in the last four quarters [2] Stock Performance - Arhaus shares have declined approximately 11.1% since the beginning of the year, compared to a 4.3% decline in the S&P 500 [3] - The current Zacks Rank for Arhaus is 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $329.52 million, and for the current fiscal year, it is $0.47 on revenues of $1.37 billion [7] - The outlook for the industry, specifically the Retail - Miscellaneous sector, is currently in the top 30% of Zacks industries, indicating a favorable environment for stock performance [8]

Core Viewpoint - BCE reported quarterly earnings of $0.48 per share, exceeding the Zacks Consensus Estimate of $0.44 per share, but down from $0.53 per share a year ago, indicating a 9.09% earnings surprise [1] - The company posted revenues of $4.13 billion for the quarter, missing the Zacks Consensus Estimate by 2.17% and down from $4.46 billion year-over-year [2] Earnings Performance - BCE has surpassed consensus EPS estimates two times over the last four quarters [2] - The company had an earnings surprise of 12% in the previous quarter, with actual earnings of $0.56 per share against an expectation of $0.50 [1][2] Stock Performance - BCE shares have declined approximately 8.3% since the beginning of the year, compared to a 4.3% decline in the S&P 500 [3] - The current Zacks Rank for BCE is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.51 on revenues of $4.2 billion, and for the current fiscal year, it is $1.96 on revenues of $17.1 billion [7] - The trend of estimate revisions for BCE is mixed, which could change following the recent earnings report [6] Industry Context - The Diversified Communication Services industry, to which BCE belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, suggesting potential challenges ahead [8]